What can we learn from brain autopsies in COVID-19?
- PMID: 33248159
- PMCID: PMC7687409
- DOI: 10.1016/j.neulet.2020.135528
What can we learn from brain autopsies in COVID-19?
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) for which there have been over 50 million confirmed cases and 1.2 million deaths globally. While many SARS-CoV-2 infected individuals are asymptomatic or experience respiratory symptoms, extrapulmonary manifestations, including neurological symptoms and conditions, are increasingly recognized. There remains no clear understanding of the mechanisms that underlie neurological symptoms in COVID-19 and whether SARS-CoV-2 has the potential for neuroinvasion in humans. In this minireview, we discuss what is known from human autopsies in fatal COVID-19, including highlighting studies that investigate for the presence of SARS-CoV-2 in brain and olfactory tissue, and summarize the neuropathological consequences of infection. Incorporating microscopic and molecular findings from brain tissue into what we know about clinical disease will inform best practice management guidance and direct research priorities as it relates to neurological morbidity from COVID-19.
Keywords: Brain autopsies; COVID-19; Immunohistochemistry; Neuropathogenesis; Neuropathology; Reverse transcriptase polymerase chain reaction; SARS-CoV-2.
Copyright © 2020 Elsevier B.V. All rights reserved.
Figures

Comment in
-
The main causes of death in patients with COVID-19.Eur Rev Med Pharmacol Sci. 2023 Mar;27(5):2165-2172. doi: 10.26355/eurrev_202303_31589. Eur Rev Med Pharmacol Sci. 2023. PMID: 36930516
References
-
- University J.H. 2020. COVID-19 Map-Johns Hopkins Coronavirus Resource Center.https://coronavirus.jhu.edu/map.html
-
- Bhimraj A., Morgan R.L., Shumaker A.H., Lavergne V., Baden L., Cheng V.C.-C., Edwards K.M., Gandhi R., Muller W.J., O’Horo J.C., Shoham S., Murad M.H., Mustafa R.A., Sultan S., Falck-Ytter Y. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa478. - DOI - PMC - PubMed
-
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. - PMC - PubMed
-
- Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L., Holden K.A., Read J.M., Dondelinger F., Carson G., Merson L., Lee J., Plotkin D., Sigfrid L., Halpin S., Jackson C., Gamble C., Horby P.W., Nguyen-Van-Tam J.S., Ho A., Russell C.D., Dunning J., Openshaw P.J., Baillie J.K., Semple M.G. ISARIC4C investigators, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous